FindMyKOL

Mark Karwal, MD

Basic profile

University of Iowa

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionIowa City, IA · MidwestSpecialtyHematology / OncologyFocusOncology
Last active 2024FindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Mark Karwal is an Oncology physician affiliated with University of Iowa. OpenAlex indexes 31 publications with 4,262 citations (h-index 10).

Overview

Scholarship

indexed output and impact (OpenAlex)
31publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

4,262citations

Citations across these publications.

10h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
4companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Merck & Co.
    Program year20254 paymentsResearch
    $19,441
  • Genentech
    Program year20251 paymentResearch
    $606
  • Merck & Co.
    Program year20246 paymentsResearch
    $37,351
All 16 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    86.5%
    Aromatase Inhibitor57.8%
    Letrozole83%Exemestane14%Anastrozole3%
    Part D<11 patients
    Estrogen Agonist/Antagonist12.8%
    Tamoxifen Citrate100%
    Part D≥22 patients

    + 2 more classes in this area

  • Metabolism & gastrointestinal

    6.9%
    Serotonin-3 Receptor Antagonist4.1%
    Ondansetron Hcl100%
    Part D≥17 patients
    Corticosteroid2.8%
    Prednisone100%
    Part D<11 patients
  • Nervous system

    4.4%
    Benzodiazepine2.5%
    Lorazepam100%
    Part D<11 patients
    Phenothiazine2%
    Prochlorperazine Maleate100%
    Part D≥11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”